Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Effect of Tergase Injection on Reducing Edema After Bilateral Total Knee Arthroplasty (ALT-TKA)

12. juli 2026 opdateret af: Man Soo Kim

A Randomized, Split Body, Evaluator-blinded, Trial on the Effect of Tergase Injection (Berahyaluronidase Alfa) on Reducing Edema After Both Total Knee Arthroplasty

This clinical trial is conducted to compare and evaluate the efficacy and safety of Tergase injection (4,500 IU) in reducing postoperative edema between treated and untreated knees in patients undergoing bilateral total knee arthroplasty (TKA).

Prior to participation, all subjects receive a full explanation of the study and provide voluntary written informed consent. Only subjects who meet the inclusion and exclusion criteria through screening procedures are enrolled. Enrolled subjects are randomly assigned to the experimental and control groups in a 1:1 ratio per knee, utilizing a split-body clinical trial design that compares both knees of the same subject.

The analysis target is 60 knees obtained from a total of 30 subjects. According to the randomization results, the knee assigned to the experimental group receives a subcutaneous injection of 3 vials (4,500 IU) of Tergase, while the contralateral knee serves as the untreated control group.

By including both the experimental and control groups within the same subject, inter-individual variation is minimized. While the investigator performing the injection is aware of the assignment, the subject remains blinded.

To overcome the physical impossibility of blinding the injector due to the route of administration and drug characteristics, an 'Evaluator-Blinded' design is adopted to maintain objectivity equivalent to a double-blind study. To achieve this, the unblinded injector and the blinded evaluator who measures efficacy outcomes are strictly separated, and operational blinding is maintained by blocking information exchange between the two groups.

Subjects are evaluated for efficacy and safety during hospitalization or outpatient visits at Day 1, 2, 3, 5, Week 2, Week 6, and Month 3 after bilateral TKA. Participation ends upon completion of the planned visits.

Studieoversigt

Status

Ikke rekrutterer endnu

Betingelser

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

30

Fase

  • Ikke anvendelig

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

  • Voksen
  • Ældre voksen

Tager imod sunde frivillige

Ingen

Beskrivelse

Inclusion Criteria:

  1. Adult males and females aged 60 years or older and 85 years or younger.
  2. Patients scheduled for bilateral total knee arthroplasty due to degenerative knee osteoarthritis with a Kellgren-Lawrence grade of III or IV confirmed by imaging within the last 4 weeks.
  3. Patients experiencing knee joint pain of 5 or higher on a 10-point Visual Analogue Scale (VAS) during daily activities, such as walking on flat ground.
  4. Patients with the willingness and ability to follow the physician's instructions, including joint exercises.
  5. Patients classified as American Society of Anesthesiologists (ASA) Physical Status Class I or II.
  6. Patients who have received a full explanation of the clinical trial and have voluntarily provided written informed consent to participate.

Exclusion Criteria:

  1. Participants or their family members with ongoing or a history of autoimmune diseases.
  2. Patients with secondary osteoarthritis of the knee.
  3. Patients with inflammatory arthritis (such as rheumatoid arthritis, lupus arthropathy, psoriatic arthritis) or crystal-induced arthropathy.
  4. Patients with a serum protein level of 5.5 g/dL or less.

  5. Patients with clinical laboratory results that are contraindications for total knee arthroplasty:

    1. WBC <3,000/μL or >12,000/μL
    2. CRP >10 mg/L
    3. Hb <10 g/dL
    4. Platelet count <100,000/μL
    5. INR >1.5
    6. eGFR <30 mL/min/1.73 m²
    7. AST or ALT >3 times the upper limit of normal
    8. Fasting blood glucose >200 mg/dL
  6. Patients with a history of drug abuse or dependence.
  7. Presence of local infection or sepsis in the affected lower limb, or a history of neurological abnormalities within the past 6 months.
  8. History of major joint surgery within 90 days.
  9. Patients who received systemic steroid treatment within 3 months prior to surgery.
  10. Patients who sustained a serious injury or received an injection in the target knee that may interfere with evaluation within 3 months prior to the screening visit.
  11. Patients with infections requiring hospitalization and administration of antibiotics or antimicrobics.

  12. Patients with any clinically significant medical condition that may interfere with study completion or outcome assessment, including but not limited to:

    1. Congenital heart disease, clinically significant cardiovascular disease, renal dysfunction, or uncontrolled diabetes.
    2. Neuromuscular disorders affecting the lower limbs.
    3. Severe bleeding or coagulation disorders.
    4. Severe knee instability that cannot be corrected with cruciate-retaining total knee arthroplasty.
    5. Severe knee deformity, defined as flexion contracture ≥30 degrees or varus/valgus deformity ≥30 degrees.
    6. Opioid dependence, defined as consumption of ≥100 mg morphine-equivalent opioids per week for more than 3 months before surgery.
    7. Inability to assess pain using the Visual Analogue Scale, including cognitive or language impairment.
    8. Venous congestion of the lower extremity.
    9. Morbid obesity, defined as body mass index >40 kg/m².
  13. History of shock or hypersensitivity to Tergase inj. or its components.
  14. Patients deemed unsuitable for this study by the investigator, such as those with psychiatric disorders.
  15. Patients currently participating in another clinical trial.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Enkelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Tergase Injection Knee
One knee of the subject, randomly assigned to receive a subcutaneous injection of 4,500 IU (3 vials) of Tergase (Berahyaluronidase alfa) at 8 points immediately after total knee arthroplasty (TKA).
Medicin: Berahyaluronidase alfa
A total dose of 4,500 IU (3.0 mL; 3 vials) of berahyaluronidase alfa is administered subcutaneously around the suture line of the randomly assigned knee immediately after total knee arthroplasty. The dose is divided into 8 injection points, approximately 0.375 mL per point.
Andre navne:
  • Rekombinant human hyaluronidase
  • Tergase Inj.
Ingen indgriben: Untreated Control Knee
The contralateral knee of the same subject which does not receive any injection, serving as a self-control for efficacy and safety comparisons.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Percent Change From Baseline in Composite Edema Index Based on Leg Circumference Measurements
Tidsramme: Baseline, Postoperative Day 2
The Composite Edema Index is calculated as the arithmetic mean of the percent change from preoperative baseline in leg circumference measured at four prespecified anatomical locations: calf at the thickest part, suprapatellar area just above the patella, infrapatellar area just below the patella, and thigh 10 cm above the patella. A higher percentage indicates greater postoperative edema.
Baseline, Postoperative Day 2

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Percent Change From Baseline in Mean Leg Circumference Swelling Rate
Tidsramme: Baseline, Postoperative Day 1, Day 3, Day 5, Week 2, Week 6, and Month 3
Mean leg circumference swelling rate is calculated as the arithmetic mean of the percent change from preoperative baseline in leg circumference measured at the same four prespecified anatomical locations. A higher percentage indicates greater postoperative swelling.
Baseline, Postoperative Day 1, Day 3, Day 5, Week 2, Week 6, and Month 3
Change From Baseline in Mean Pain Intensity Score on a 0-to-10 Visual Analog Scale
Tidsramme: Baseline, Postoperative Day 1, Day 2, Day 3, Day 5, Week 2, Week 6, and Month 3
Pain intensity is assessed using a 0-to-10 visual analog scale, where 0 indicates no pain and 10 indicates the worst imaginable pain. The mean pain intensity score is calculated as the arithmetic mean of pain scores assessed at rest, during 60-degree knee flexion, and during walking. A higher score indicates greater pain intensity.
Baseline, Postoperative Day 1, Day 2, Day 3, Day 5, Week 2, Week 6, and Month 3
Change From Baseline in Active Knee Flexion Range of Motion Measured With a Goniometer
Tidsramme: Baseline, Postoperative Day 1, Day 2, Day 3, Day 5, Week 2, Week 6, and Month 3
Active knee flexion range of motion is measured in degrees using a goniometer. A higher value indicates greater knee flexion range of motion.
Baseline, Postoperative Day 1, Day 2, Day 3, Day 5, Week 2, Week 6, and Month 3
Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index Total Score
Tidsramme: Baseline, Week 6, and Month 3
The Western Ontario and McMaster Universities Osteoarthritis Index is a self-reported questionnaire consisting of 24 items across three domains: pain, stiffness, and physical function. The total score ranges from 0 to 96, with higher scores indicating greater pain, stiffness, and functional impairment.
Baseline, Week 6, and Month 3
CT-Measured Mean Lower Extremity Soft Tissue Thickness at Postoperative Day 2
Tidsramme: Postoperative Day 2
Lower extremity CT scans are used to measure soft tissue thickness at prespecified anatomical locations corresponding to the circumference measurement sites. The value is reported in millimeters as the mean thickness across the prespecified locations. A higher value indicates greater soft tissue thickness.
Postoperative Day 2
Change From Baseline in Serum C-Reactive Protein Concentration
Tidsramme: Baseline, Postoperative Day 1, Week 2, and Month 3
Serum C-reactive protein concentration is measured using fasting blood samples to evaluate the systemic inflammatory response after surgery. Values are reported in mg/L. A higher value indicates a greater inflammatory response.
Baseline, Postoperative Day 1, Week 2, and Month 3
Change From Baseline in Serum Amyloid A Concentration
Tidsramme: Baseline, Postoperative Day 1, Week 2, and Month 3
Serum amyloid A concentration is measured using fasting blood samples to evaluate the systemic inflammatory response after surgery. Values are reported in mg/L. A higher value indicates a greater inflammatory response.
Baseline, Postoperative Day 1, Week 2, and Month 3
Number of Participants With at Least One Predefined Postoperative Complication
Tidsramme: From immediately after surgery through postoperative Month 3
Predefined postoperative complications include nausea, vomiting, falls, subcutaneous hemorrhage, vascular injury, wound complications, and venous thromboembolism. Participants are counted once if they experience one or more predefined postoperative complications during the assessment period.
From immediately after surgery through postoperative Month 3
Number of Participants With at Least One Adverse Event
Tidsramme: From investigational product administration through postoperative Month 3
Adverse events and serious adverse events occurring after investigational product administration are collected during the study period. Participants are counted once if they experience one or more adverse events, excluding predefined postoperative complications captured separately.
From investigational product administration through postoperative Month 3
Number of Participants With Clinically Significant Abnormal Vital Sign Findings
Tidsramme: From Screening Visit through postoperative Month 3
Clinically significant abnormal vital sign findings are defined as any investigator-assessed clinically significant abnormality in blood pressure, pulse rate, or body temperature during the study period. Participants are counted once if they experience one or more clinically significant abnormal vital sign findings.
From Screening Visit through postoperative Month 3
Number of Participants With Clinically Significant Abnormal Physical Examination Findings
Tidsramme: From Screening Visit through postoperative Month 3
Clinically significant abnormal physical examination findings are defined as any new or worsened abnormal finding identified by the investigator during the study period. Participants are counted once if they experience one or more clinically significant abnormal physical examination findings.
From Screening Visit through postoperative Month 3
Number of Participants With Clinically Significant Abnormal Clinical Laboratory Test Results
Tidsramme: From Screening Visit through postoperative Month 3
Clinically significant abnormal clinical laboratory test results are defined as any investigator-assessed clinically significant abnormality in hematology, blood chemistry, coagulation, or urinalysis results during the study period. Participants are counted once if they experience one or more clinically significant abnormal clinical laboratory test results.
From Screening Visit through postoperative Month 3

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Man Soo Kim

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Generelle publikationer

Hjælpsomme links

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Anslået)

1. august 2026

Primær færdiggørelse (Anslået)

31. januar 2028

Studieafslutning (Anslået)

31. marts 2028

Datoer for studieregistrering

Først indsendt

14. maj 2026

Først indsendt, der opfyldte QC-kriterier

12. juli 2026

Først opslået (Faktiske)

15. juli 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

15. juli 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

12. juli 2026

Sidst verificeret

1. juli 2026

Mere information

Begreber relateret til denne undersøgelse

Nøgleord

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

  • XC26MIDI0010
  • KCT0011945 (Registry Identifier: Clinical Research Information Service (CRIS))

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Kliniske forsøg med Slidgigt, knæ

Kliniske forsøg med Berahyaluronidase alfa

Søg i lignende forsøg

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

CROs by country

CROs in Gabon

Betingelser

Sjældne sygdomme

Narkotikainterventioner

Kosttilskud

Sponsor / samarbejdspartnere

Placeringer

3
Abonner